DE69333115D1 - Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren - Google Patents

Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Info

Publication number
DE69333115D1
DE69333115D1 DE69333115T DE69333115T DE69333115D1 DE 69333115 D1 DE69333115 D1 DE 69333115D1 DE 69333115 T DE69333115 T DE 69333115T DE 69333115 T DE69333115 T DE 69333115T DE 69333115 D1 DE69333115 D1 DE 69333115D1
Authority
DE
Germany
Prior art keywords
gene
particles
hapten
retroviral
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333115T
Other languages
English (en)
Inventor
Stephen James Russell
Robert Edward Hawkins
Gregory Paul Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofocus Discovery Ltd
Original Assignee
Biofocus Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220010A external-priority patent/GB9220010D0/en
Priority claimed from GB939304962A external-priority patent/GB9304962D0/en
Application filed by Biofocus Discovery Ltd filed Critical Biofocus Discovery Ltd
Application granted granted Critical
Publication of DE69333115D1 publication Critical patent/DE69333115D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
DE69333115T 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren Expired - Lifetime DE69333115D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929220010A GB9220010D0 (en) 1992-09-22 1992-09-22 Recombinant virus
GB939304962A GB9304962D0 (en) 1993-03-11 1993-03-11 Recombinant virus
PCT/GB1993/001992 WO1994006920A1 (en) 1992-09-22 1993-09-22 Recombinant viruses displaying a nonviral polypeptide on their external surface

Publications (1)

Publication Number Publication Date
DE69333115D1 true DE69333115D1 (de) 2003-08-28

Family

ID=26301664

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333115T Expired - Lifetime DE69333115D1 (de) 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Country Status (8)

Country Link
US (2) US5723287A (de)
EP (1) EP0670905B1 (de)
JP (1) JPH08504091A (de)
AT (1) ATE245703T1 (de)
AU (1) AU689755B2 (de)
CA (1) CA2145063A1 (de)
DE (1) DE69333115D1 (de)
WO (1) WO1994006920A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504091A (ja) * 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
EP0746625B1 (de) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
EP0672129A4 (de) * 1992-11-20 1997-06-11 Univ New Jersey Med Zelltyp spezifischer gentransfer mit hilfe von retroviralen vektoren welche antikörper-hülle fusionsproteine haben.
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
FR2724320B1 (fr) 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
GB9514368D0 (en) * 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
GB9516138D0 (en) * 1995-08-05 1995-10-04 Medical Res Council Improvements in or relating to methods of screening substances
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
JP2000504220A (ja) * 1996-01-23 2000-04-11 ライガル ファーマシューティカルズ インコーポレイテッド トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
AU2670397A (en) * 1996-04-08 1997-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Reagent and method for targeting retrovirus
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
ATE388720T1 (de) 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
AU7727298A (en) * 1997-06-06 1998-12-21 Regents Of The University Of Michigan, The Neuregulin response element and uses therefor
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
WO1999060110A2 (en) 1998-05-20 1999-11-25 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
AU5465899A (en) * 1998-08-04 2000-02-28 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
JP2002526756A (ja) * 1998-09-24 2002-08-20 デューク ユニバーシティ 生細胞におけるタンパク質−タンパク質相互作用の測定方法
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
DE60044514D1 (de) 1999-05-05 2010-07-15 Phylogica Ltd Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielvältigen Genfragmenten
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
WO2000073478A2 (en) * 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
WO2001021216A1 (en) * 1999-09-24 2001-03-29 The Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US6635476B1 (en) * 1999-10-15 2003-10-21 Canji, Inc. Targeted vectors
CA2393869A1 (en) * 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2401623A1 (en) 2000-02-25 2001-08-30 Biofocus Discovery Limited Methods and compositions for identifying a protease
EP1282727A1 (de) 2000-02-25 2003-02-12 Biofocus Discovery Limited Verfahren zum identifizieren von potentielle protease-kodierende polynukleotide
ES2253358T3 (es) 2000-03-31 2006-06-01 Cambridge Antibody Technology Limited Mejoras en la visualizacion del ribosoma.
US6762031B2 (en) * 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
DE60126130T2 (de) * 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
EP1478751A4 (de) 2001-03-30 2005-10-19 Avigenics Inc Lysozym-promotor in vögeln
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
WO2003102219A2 (en) * 2002-06-04 2003-12-11 Purdue Research Foundation Improved pseudotyped retroviruses
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
AU2002359568B2 (en) 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US7132237B2 (en) * 2002-03-13 2006-11-07 Mayo Foundation For Medical Education And Research Avian leukosis viruses and polypeptide display
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7329486B2 (en) * 2003-03-31 2008-02-12 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
AU2005250511B2 (en) * 2004-06-03 2012-01-19 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
US7875275B2 (en) 2004-06-16 2011-01-25 The General Hospital Corporation Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
CA2572467A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
WO2006019904A1 (en) 2004-07-14 2006-02-23 University Of Utha Research Foundation Netrin-related compositions and uses
US8828727B2 (en) 2004-07-21 2014-09-09 Dana-Farber Cancer Institute Lentiviral vectors and uses thereof
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP1947181A4 (de) 2005-11-24 2010-09-22 Genomidea Inc Mutantes paramyxovirus und verfahren zur herstellung davon
DK1987178T3 (en) * 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
PT2520168E (pt) 2006-07-21 2014-04-29 California Inst Of Techn Administração de gene alvo para vacinação de células dendríticas
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
WO2008053486A1 (en) * 2006-11-02 2008-05-08 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
ATE501280T1 (de) * 2007-04-04 2011-03-15 Chimera Biotec Gmbh Verfahren zum nachweis eines analyten in einer biologischen matrix
US8822409B2 (en) * 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
ATE523603T1 (de) 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
CA2755870C (en) 2009-03-20 2019-04-09 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
US20120213744A1 (en) 2009-04-27 2012-08-23 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
WO2010135558A1 (en) * 2009-05-20 2010-11-25 Novimmune S.A. Systhetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
PL2456786T5 (pl) 2009-07-24 2017-10-31 Immune Design Corp Wektory lentiwirusowe pseudotypowane glikoproteiną otoczki wirusa sindbis
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US10208304B2 (en) * 2011-04-14 2019-02-19 Regents Of The University Of Minnesota Adenovirus library and methods
JP6038121B2 (ja) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
EP2844746A4 (de) 2012-03-26 2016-07-20 Univ California Pseudotypisierte lentiviren mit nipah-virus-hüllen und verfahren zu deren verwendung
EA038702B1 (ru) 2012-03-30 2021-10-07 Иммьюн Дизайн Корп. Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EP3008043A2 (de) 2013-06-14 2016-04-20 University Of Utah Research Foundation Triazol-1-ol analoge antiretrovirale latenzarzneimittel
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US20160279207A1 (en) 2015-03-10 2016-09-29 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
EP3331562A2 (de) 2015-08-06 2018-06-13 Xoma (Us) Llc Antikörperfragmente gegen den insulinrezeptor und verwendungen davon zur behandlung von hypoglykämie
WO2017201281A1 (en) * 2016-05-18 2017-11-23 Mayo Foundation For Medical Education And Research Targeting pd-l1 on tumor cells
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
CN110869507A (zh) 2017-05-08 2020-03-06 旗舰先锋创新V股份有限公司 促进膜融合的组合物和其用途
ES2967696T3 (es) 2019-04-08 2024-05-03 Giuseppe Scalabrino Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
JPH06500923A (ja) * 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
DE69131908T3 (de) * 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
AU3434393A (en) * 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
EP0633943A4 (de) * 1992-04-03 1997-05-02 Alexander T Young Gentherapy unter verwendung zielgerichteter viraler vektoren.
JPH08504091A (ja) * 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス

Also Published As

Publication number Publication date
EP0670905B1 (de) 2003-07-23
US5723287A (en) 1998-03-03
ATE245703T1 (de) 2003-08-15
JPH08504091A (ja) 1996-05-07
CA2145063A1 (en) 1994-03-31
AU4827893A (en) 1994-04-12
AU689755B2 (en) 1998-04-09
EP0670905A1 (de) 1995-09-13
WO1994006920A1 (en) 1994-03-31
US6297004B1 (en) 2001-10-02

Similar Documents

Publication Publication Date Title
DE69333115D1 (de) Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
Kasahara et al. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
Marin et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins
Jones et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells
Lavillette et al. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments
Siomi et al. Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing
Craven et al. Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras
Morizono et al. Role of phosphatidylserine receptors in enveloped virus infection
Goila-Gaur et al. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression
ATE317909T1 (de) Verabreichung von komplettem faktor viii mit hilfe eines retroviralen systems
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
GR3022850T3 (en) Synthetic DNA derived recombinant HIV-1 antigens
AU1189195A (en) Recombinant protein production in bovine adenovirus expression vector system
US6534051B1 (en) Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
Manel et al. Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1
Chadwick et al. Modification of retroviral tropism by display of IGF-I
Battini et al. Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor
US6448390B1 (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
Masood et al. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors
Dervillez et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV‐1 fusion inhibitory peptide C46
Guibinga et al. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
Bachrach et al. Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein
Piechaczyk Cell targeting by murine retroviral vectors
Katane et al. Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein

Legal Events

Date Code Title Description
8332 No legal effect for de